Sarepta Therapeutics, Inc. the leader in precision genetic medicine for rare diseases, announced that it has closed on a $600 million senior secu...
Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, reported its consolidated financial results for the fourth quarter and full year ...
Pfizer Inc. reported robust financial results for the full year 2024, achieving total revenues of $63.6 billion, reflecting a 7% year-over-year operation...
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, provided an update on the progres...
Company embarks on a vision to make cardiovascular disease curable, preventable, and no longer the leading cause of death worldwide Led by found...
Andreessen Horowitz (a16z) Bio + Health announced a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health...
An indictment unsealed on charged the former chief scientific officer of biopharmaceutical company Humanigen (0KB2.BE), opens new tab with engagi...
Catalent, Inc. (“Catalent”), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S...
BD (Becton, Dickinson and Company) , a leading global medical technology company, issued the following statement: BD has reached an agreement with...
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) announced that it will proceed with a 1-for-20 reverse stock sp...
DANNCE.AI raised $2.6 million in pre-seed funding led by LDV Capital, following initial investment from Glasswing Ventures, with participation from The L...
NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hyd...
Financial report for the period 1 January 2024 to 30 September 2024 &nb...
Bionomics , a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from s...
© 2025 Biopharma Boardroom. All Rights Reserved.
